IRAK4-IN-17
IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC50 of 1.3 nM. IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research.
For research use only. We do not sell to patients.
- CAS No.: 2183503-33-3
- Formula: C17H20F2N8O
- Molecular Weight:390.39
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
IRAK4 1.3 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT | IC50 |
40.1 μM
Compound: 5
|
Cytotoxicity against human HT cells harboring MYD88 assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Cytotoxicity against human HT cells harboring MYD88 assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 32014679] |
| OCI-Ly10 | IC50 |
0.7 μM
Compound: 5
|
Cytotoxicity against human OCILY10 cells harboring MYD88 L265P mutant assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Cytotoxicity against human OCILY10 cells harboring MYD88 L265P mutant assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 32014679] |
| Ramos | IC50 |
11.4 μM
Compound: 5
|
Cytotoxicity against human Ramos cells harboring MYD88 assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Cytotoxicity against human Ramos cells harboring MYD88 assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 32014679] |
| TMD8 | IC50 |
1.2 μM
Compound: 5
|
Cytotoxicity against human TMD8 cells harboring MYD88 L265P mutant assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Cytotoxicity against human TMD8 cells harboring MYD88 L265P mutant assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 32014679] |
IRAK4-IN-17 (0.7-40.1 μM; 72 h) selectively suppresses OCI-LY10 and TMD8 cells with MYD88 L265P mutation[1].
IRAK4-IN-17 (0.3-10 μM; 2 h) inhibits the viability of DLBCL cells by targeting IRAK4 signaling[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:OCI-LY10, TMD8, Ramos and HT cells
-
Concentration:0.7-40.1 μM
-
Incubation Time:72 hours
-
Result:Suppressed OCI-LY10 and TMD8 cells with MYD88 L265P mutation (IC50=0.7 μM and 1.2 μM, respectively), but not Ramos and HT cell lines with WT MYD88 (IC50=11.4 μM and 40.1 μM, respectively).
-
Cell Line:OCI-LY10 and TMD8 cells
-
Concentration:0.3, 1, 3 and 10 μM
-
Incubation Time:2 hours
-
Result:Inhibited the phosphorylation of IRAK4 and the downstream molecules, IKKβ and NF-κB transcription factor (p65) in OCI-LY10 and TMD8 cells.
Chemical Information
-
CAS No. 2183503-33-3
-
Molecular Weight 390.39
-
Formula C17H20F2N8O
-
SMILES
O=C(C1=CN=C2C=CC(N[C@H]3CNCCC3)=NN21)NC4=CN(C)N=C4C(F)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
IRAK4-IN-17 Related Classifications
HY-150594 Related Classifications
Powered by Bioz